Presentation to Aquis Showcase Event
7 November 2024
AQSE: EDX
("EDX Medical" or the "Company")
PRESENTATION TO AQUIS SHOWCASE EVENT
CAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces today that the Company will be presenting at the Aquis Showcase Event on Tuesday, 12 November 2024 at the Royal College of Surgeons, London.
Eric Vick, chief commercial officer of EDX Medical will be representing the Company. There will be a presentation to delegates between 1pm and 1.30pm and senior management from the Company will be available throughout the day to engage with investors.
The Aquis Showcase Event is a one-day event with companies presenting and competing in an investment contest, to be judged by a panel of experts and those in attendance.
EDX Medical investors are encouraged to attend the event and watch the presentation. For further information on the Aquis Showcase Event, and to purchase tickets, please visit the event website here: Aquis Showcase Event.
The Directors of the Company accept responsibility for the contents of this announcement.
Contacts:
|
EDX Medical Group Plc |
|
|
Dr Mike Hudson (Chief Executive Officer) |
+44 (0)7812 345 301 |
|
|
|
|
Oberon Capital |
|
|
Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking) |
+44 (0)20 3179 5300 |
|
|
|
|
Media House International |
|
|
Ramsay Smith
Gary McQueen |
+44 (0)7788 414856 ramsay@mediahouse.co.uk + 44 (0)7834 694609 gary@mediahouse.co.uk |
|
IFC Advisory (Investor Relations) |
|
|
Tim Metcalfe |
+44 (0)20 3934 6630 |
|
Graham Herring |
|
Notes for Editors:
About EDX Medical Group plc
The EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.
EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.
EDX Medical conducts product development, validation and distribution to ISO 13485 and provides PCR services accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 4 hours ago Alphawave IP Group
- 4 hours ago WH Smith
- 5 hours ago Staffline Group
- 5 hours ago Manchester & London Investment Trust
- 6 hours ago Associated British Foods